-
Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come
Tuesday, March 31, 2015 - 10:30am | 257Read More...Oppenheimer upgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) Tuesday from Perform to Outperform and set a price target of $77. Analysts Akiva Felt and Angad Verma expected more deals to come following the announcement that the company would acquire Auspex Pharmaceuticals Inc (...
